Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

Citrome; L.

首页> 外文期刊>Expert review of neurotherapeutics >Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

【24h】

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

机译：Tardive Dyskinesia：将凹凸单胺转运蛋白2（VMAT2）抑制剂放入临床视角

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Tardive dyskinesia (TD) is an iatrogenic movement disorder caused by exposure to dopamine receptor blocking agents. Two vesicular monoamine transporter type 2 (VMAT2) inhibitors for the treatment of TD were approved by the US Food and Drug Administration in 2017: valbenazine and deutetrabenazine. Areas covered: A brief review of TD and its identification, as well as a review of older treatment interventions is provided, followed by a detailed synthesis regarding the clinical utility of valbenazine and deutetrabenazine. Expert commentary: As evidenced from well-designed clinical trials, both valbenazine and deutetrabenazine are efficacious and tolerable. They differ in terms of labeled instructions for frequency of administration (twice daily for deutetrabenazine vs. once daily for valbenazine), titration requirements (dose to efficacy/tolerability for deutetrabenazine vs. titrate to target dose of 80 mg/day for valbenazine), need for food (administer deutetrabenazine with food), drug-drug interactions (consider CYP2D6 modulators for deutetrabenazine vs. both CYP2D6 and CYP3A4 for valbenazine), contraindications (hepatic impairment for deutetrabenazine), and minor differences in adverse event profile.

机译：介绍：Tardive Dyskinesia（TD）是由暴露于多巴胺受体阻塞剂引起的发育运动障碍。用于治疗TD的两种尿素单胺转运蛋白2（VMAT2）抑制剂于2017年通过美国食品和药物管理局批准：缬沙嗪和氘甲苯杂志。涵盖了地区：对TD及其鉴定的简要审查，以及对较老的治疗干预措施的审查，其次是关于缬沙嗪和氘化碱的临床效用的详细合成。专家评论：从设计精心设计的临床试验中证明，缬沙嗪和氘甲苯碱都是有效可忍受的。它们在标记的给药频率指令方面不同（每天两次用于甲萘嗪每天每天一次），滴定要求（氘代/滴定滴定滴定滴定为缬沙嗪的靶剂量为80mg /天），需要对于食物（用食物施用氘甲苯碱），药物 - 药物相互作用（考虑CYP2D6调节剂，用于氘二烷嗪的CYP2D6和CYP3A4，对缬沙嗪的CYP2D6和CYP3A4进行），禁忌症（氘代苯甲嗪的肝脏损伤），以及不良事件概况的微小差异。

著录项

来源
《Expert review of neurotherapeutics》 |2018年第6期|共10页
作者
Citrome; L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective [J] . Citrome, L. Expert review of neurotherapeutics . 2018,第1a6期

机译：Tardive Dyskinesia：将凹凸单胺转运蛋白2（VMAT2）抑制剂放入临床视角
2. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects [J] . Stephen M.Stahl CNS spectrums . 2018,第1期

机译：腐败的止吐管瘤中的凹凸单胺转运蛋白2（VMAT2）抑制剂的作用机制：减少多巴胺导致从电机纹状体的较低“去”，更“止挡”，以稳健的治疗效果
3. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management [J] . Venkatesh Sreeram, Shanila Shagufta, Faisal Kagadkar Cureus. . 2019,第8期

机译：尿素单胺转运蛋白2抑制剂在Tardive Dyskinesia管理中的作用
4. Design, synthesis, and pharmacological evaluation of three series of lobelane analogs as inhibitors of the vesicular monoamine transporter (VMAT2). [D] . Culver, John P. 2015

机译：设计，合成和药理学评估三个系列的环氧丙烷类似物作为水泡单胺转运蛋白（VMAT2）的抑制剂。
5. Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia [O] . Boris Karl, Hanna Bergman, Sarah Abd El Sayed, -1

机译：水泡单胺转运蛋白抑制剂与安慰剂的抗精神病药性迟发性运动障碍
6. Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. [O] . Jianjun Sun, Jinbin Xu, Nigel J Cairns, 2012

机译：多巴胺D1，D2，D3受体，囊泡单胺转运蛋白2型（VmaT2）和多巴胺转运蛋白（DaT）在老年人脑中的密度。

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

摘要

著录项

相似文献

相关主题

期刊订阅